Author

T. Hackert

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 4 Research Focus:cell type annotation· 3 Research Focus:differential expression· 2 Approach:experimental assay· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

A. Ahmed· 1 shared A. Fischer· 1 shared A. M. Schlitter· 1 shared A. Maida· 1 shared A. Mhamane· 1 shared A. Weider· 1 shared A. Zeigerer· 1 shared B. Ekim-Uestuenel· 1 shared

Activity by Year

2021-2021 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Ahmed

Author profile →

4 papers

Recent·Most cited

Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function

G. Wolff, M. Sakurai, A. Mhamane, A. Maida, I. K. Deligiannis, K. Yin, P. Weber, A. Weider, M. Troullinaki, A. Zeigerer, M. Roden, N. Volk, T. Poth, T. Hackert, L. Wiedmann, , S. Herzig

This study shows that deleting TSC22D4 in hepatocytes reduces liver damage in NASH by improving mitochondrial function and lipid metabolism.

bioRxiv · Dec 17, 2021Physiology

GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma

M. P. de Andres, R. Jackson, C. Pilarsky, A. M. Schlitter, E. Costello, W. Greenhalf, P. Ganeh, T. Knoesel, D. Palmer, P. Ruemmele, W. Weichert, M. Buechler, T. Hackert, J. P. Neoptolemos, N. Malats, , F. X. Real

This study shows that low GATA4 and GATA6 expression in pancreatic ductal adenocarcinoma (PDAC) is linked to worse patient outcomes and loss of the classical tumor phenotype.

bioRxiv · Aug 9, 2021Cancer Biology

Langerhans islets induce anti-tumor immunity at the expense of glycemic control and predict chemotherapy response in pancreatic cancer

A. Ahmed, P. Charoentong, R. Klotz, S. Koehler, M. Suarez-Carmona, N. A. Valous, D. Ferber, M. Heikenwaelder, N. Giese, T. Hackert, F. Klupp, M. Schneider, T. Schmidt, C. Springfeld, Y. Tanriver, , N. Halama

This study shows that Langerhans islets in pancreatic tumors promote anti-tumor immunity but impair glycemic control, and identifies T2DM and HbA1c as predictors of chemotherapy response.

bioRxiv · Mar 13, 2021 · PreprintCancer Biology

Towards 3D-Bioprinting of an Endocrine Pancreas: A Building-Block Concept for Bioartificial Insulin-Secreting Tissue

G. A. Salg, E. Poisel, M. Neulinger-Munoz, D. Cebulla, V. Vieira, C. Bludszuweit-Philipp, F. Nickel, I. Herr, N. A. Giese, T. Hackert, H. G. Kenngott

This study develops a 3D-bioprinting approach to create insulin-secreting pseudoislets, demonstrating viability, proliferation, and functional responses in vitro and in vivo.

bioRxiv · Feb 27, 2021Bioengineering